Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurati

BenzingaApr 17 02:25

Avalo Therapeutics Raised to Outperform From Perform by Oppenheimer

Avalo Therapeutics Raised to Outperform From Perform by Oppenheimer

Dow JonesApr 16 21:03

Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target

Oppenheimer analyst Leland Gershell upgrades Avalo Therapeutics (NASDAQ:AVTX) from Perform to Outperform and announces $35 price target.

BenzingaApr 16 20:52

Avalo Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 118.07% Oppenheimer → $35 Upgrades Perform → Outperform 06/27/2023 — Oppenheimer Downgrades Ou

BenzingaApr 16 20:51

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $

BenzingaApr 10 04:31

SOL, MESO and ACOR Among Pre-market Losers

Seeking AlphaApr 3 20:12